title: Comment on: Bisphosphonates and osteonecrosis of the jaw.
authors.forename: M L
authors.initials: ML
authors.lastname: Bianchi
authors.forename: C
authors.initials: C
authors.lastname: Limonta
authors.forename: J
authors.initials: J
authors.lastname: Frasunkiewicz
authors.forename: M
authors.initials: M
authors.lastname: Biggioggero
authors.forename: S
authors.initials: S
authors.lastname: Vai
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D019386:Alendronate / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced* / Q000503:physiopathology; D000077268:Pamidronate; D011446:Prospective Studies; D018570:Risk Assessment
chemical_list: D004164:Diphosphonates; D000077268:Pamidronate; D019386:Alendronate